Gamma Knife Radiosurgery for Brain Vascular MalformationsEditor(s): Niranjan A. (Pittsburgh, Pa.)
Kano H. (Pittsburgh, Pa.)
Lunsford L.D. (Pittsburgh, Pa.)
Natural History of Cerebral Arteriovenous Malformations and the Risk of Hemorrhage after RadiosurgeryYen C.-P. · Schlesinger D. · Sheehan J.P.
Department of Neurological Surgery, University of Virginia, Charlottesville, Va., USA
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
The annual hemorrhage rate of intracranial arteriovenous malformations (AVMs) varies from 2 to 4%. In a patient with decades of life ahead, the cumulative risk of hemorrhage is significant. AVMs exhibiting characteristics such as deep venous drainage, venous stenosis, associated aneurysms and feeders from perforators are associated with an elevated risk of hemorrhage. We reviewed 1,400 AVM patients who underwent Gamma Knife surgery (GKS) at the University of Virginia between 1989 and 2009. The dose selection was based on the size and location of the nidus. The mean prescription dose was 21.2 Gy (range 5–36 Gy), and the mean maximum dose was 39.4 Gy (range 10–60 Gy). A total of 657 patients suffered 803 hemorrhagic events over 42,495 risk years before GKS. Assuming that these patients were at risk for hemorrhage since birth, the annual hemorrhage rate was 2.0%. If we calculate the hemorrhage rate after the diagnosis of the AVMs, the hemorrhage rate was 6.6%. Following GKS and prior to a radiographic documented obliteration, the annual hemorrhage rate was 2.5%; this rate is very similar to the 2.0% one computed prior to radiosurgery by assuming AVMs to be congenital. Once angiographic obliteration was confirmed after GKS, the hemorrhage rate dropped to zero.
© 2013 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.